IFAPP Academy, MAPS Offer Medical Affairs Course
IFAPP Academy and the Medical Affairs Professional Society (MAPS) are offering an online course for medical affairs professionals looking to [...]
Measuring Care Value
Stacey Richter, Relentless Health Value host and Aventria Health Group co-founder, discusses metrics for measuring care value in the latest [...]
Capital Rx CEO Talks Price Transparency
Capital Rx CEO A.J. Loiacono in a new Patients Rising Podcast discusses the importance of price transparency at the pharmacy [...]
Cytel COVID-19 Clinical Development Quiz
Cytel is offering a quiz for users to gauge their knowledge on the state of COVID-19 clinical development across the [...]
OptumRx’s Calabrese: Top 3 Drugs in Pipeline
OptumRx Senior Vice President and Chief Pharmacy Officer David Calabrese in a recent interview with Managed Healthcare Executive discusses the [...]
ACS Researchers Receive RWD Award
Three American Cancer Society researchers have been awarded the Real-World Data Impact Award, ACS and Flatiron Health announced this week. [...]
McClellan Stresses Need for RWE Infrastructure
Duke-Margolis' Mark McClellan tells The Pink Sheet a robust real-world evidence infrastructure is needed, and that RWE studies should be [...]
Gupta: Five Trends That Have Accelerated in 2020
Heron Therapeutics' Anita Gupta in a recent piece published on Forbes highlights five key trends that have accelerated during the [...]
Panel Discusses Provider Prospective on Value-Based Care for mBC
A recent panel discussion on AJMC's Peer Exchange discusses how providers identify value-based care opportunities for metastatic breast cancer. The [...]
ICER Posts White Paper on Alternative Pricing Policies During Pandemic
The Institute for Clinical and Economic Review (ICER) announced the release of a new white paper on alternative policies for [...]
Study Finds Inconsistent Reimbursement Assessments Across EU Markets
While some modifications in the HTA process for orphan drugs have had some positive impacts, manufacturers still face key hurdles [...]
ICER Cancels Meeting for Non-Alcoholic Steatohepatitis Assessment
The Institute for Clinical and Economic Review (ICER) has canceled the August meeting of the Midwest CEPAC. The meeting was [...]
Evidation Looks to Bolster Platform to Include Virtual Treatment
After generating $45 million in investments, Evidation is looking to expand its virtual research platform to include digital interventions and [...]
ISPOR Course on Payment Models Nears
Registration is still open for the International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) upcoming short course on risk-sharing and [...]
ISPOR Short Course on Medical Devices is Tomorrow
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) short course on market access and value assessment of medical devices [...]
Webinar on Future of Primary Care Set for July 28
World Congress is set to host a webinar July 28 on the future of primary care. The hour-long event, "The [...]
Blog Post Explores Key Issues in De-Implementation
The last installment of a four-part blog series by AcademyHealth's Research Community on Low-Value Care looks at some key hurdles [...]
Siami: NESTcc at ‘Pivot Point’
Sandra Siami, the new head of the National Evaluation System for health Technology Coordinating Center (NESTcc), tells MedTech Dive the [...]
Thompson Spotlights Virtual Research
Syneos Health's David Thompson in a recent Value & Outcomes Spotlight article spotlights how drugmakers are dealing with increased emphasis [...]
PRMA’s Chadwick Highlights Common Omissions in Global Value Dossiers
PRMA Consulting HTA Manager Claire Chadwick in a recent blog post discusses five common omissions in global value dossiers. Chadwick [...]
Value & Outcomes Spotlight Editor-in-Chief Bids Farewell in Latest Issue
Value & Outcomes Spotlight Editor-in-Chief David Thompson bid readers farewell in the latest issue, describing his 12-plus years in the [...]
Report: Responses to Remdesivir Price Mostly Negative
Even though the Institute for Clinical for Economic Review (ICER) announced its support of remdesivir's pricing, the response has been [...]
Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent [...]
Healthcare Reimbursement Market to Reach $20 billion by 2025, Report Suggests
The U.S. healthcare reimbursement market could be valued at $20 billion by 2025, according to a new report by Brand [...]
Report: FDA Mandates 50% Efficacy for COVID-19 Vaccines
Vaccine candidates must be at least 50 percent more effective than a placebo to be considered for Food and Drug [...]